Home Featured Page 203

Featured

Latest

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical, and Increasingly Coordinated

Bit Yaden on Preparing the Next Generation of Psychiatrists for a Psychedelic Future

“If I can’t change my views based on evidence, then why do science at all?” Nora Volkow on Psychedelics

Q4 2025: Oregon Psilocybin Services Update

Psilocybin for Chronic Suicidal Ideation: Scott T. Aaronson on Safety, an Efficacy Signal, and the Role of Expectations

Two thirds of physicians surveyed believe psilocybin therapy has potential benefit...

Psygen Receives Dealer’s Licence from Health Canada

Red Light Holland to Collaborate with Advocacy Group, Psychedelic Medicine Alliance...

Optimi Health Submits Natural Psilocybin Combined Drug Delivery and Extraction Formulations...

Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Psychedelics Today

BetterLife Obtains Positive In Vivo Oral Bioavailability, Food Effect and Pharmacokinetics...

Entheon Biomedical Corp. Files Preliminary Shelf Prospectus

Mydecine Signs LOI with The Newly Institute to Provide Psychedelic-Assisted Psychotherapy...

MindMed Enrolls First Participant in a Study of its Session Monitoring...

PT285 – Andrew Penn, NP – The Need for Nurses in...

EDITOR PICKS

At the Federal Psychedelic Medicine Summit, the Mood Was Urgent, Practical,...

Bit Yaden on Preparing the Next Generation of Psychiatrists for a...

“If I can’t change my views based on evidence, then why...

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.